bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: O S A J J M A M F J
2016: D N O

 
  Other news for:
Neoplasms
 Resources from HONselect
Mvasi Is First Biosimilar Drug Approved for Cancer
Similar to Avastin

By Scott Roberts

THURSDAY, Sept. 14, 2017 (HealthDay News) -- The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration.

Mvasi (bevacizumab-awwb) was found to be biosimilar to the anti-cancer drug Avastin, the FDA said Thursday in a news release. Avastin was approved in 2004.

Biosimilar drugs are typically derived from living organisms and are approved after manufacturers demonstrate that the medications are "highly similar" to already approved drugs, the agency said.

Mvasi is approved to treat certain cancers of the colon, lung, brain, kidney and cervix, the FDA said.

"Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to help spur competition that can lower healthcare costs and increase access to important therapies," said FDA Commissioner Dr. Scott Gottlieb. He pledged new biosimilar drugs would be brought to market quickly, although subject to FDA's "rigorous gold standard for safety and effectiveness."

The most common side effects of Mvasi include nose bleed, headache, high blood pressure, nasal inflammation, abnormally high urinary protein, changes in taste and dry skin. More serious adverse reactions could include abnormal connections between internal organs, blood clots, high blood pressure and problems with brain function.

Like Avastin, labeling for Mvasi will warn of increased risk of gastrointestinal holes, complications after surgery and severe bleeding of the lungs, stomach, intestines, central nervous system and female genitalia.

Mvasi's approval was given to Amgen, based in Thousand Oaks, Calif. Avastin is produced by Genentech Inc.

More information

The FDA has more about this approval.

SOURCE: Sept. 14, 2017 media release, U.S. Food and Drug Administration

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=726559

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Blood
Specialty Chemicals and Products
Brain
Lung
Hypertension
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact